Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Scott

Showing results (321-330 of 360) with videos related to

Pageof 36
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinomaGeoffrey Chong, Fook Thean Lee, Wendie Hopkins, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 9, 2013
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemiaDavid S Ritchie, Paul J Neeson, Amit Khot, et al.
The Lancet. Oncology|September 13, 2024
[<sup>89</sup>Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trialBrian Shuch, Allan J Pantuck, Jean-Christophe Bernhard, et al.
Gynecologic Oncology|June 1, 2015
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinomaOren Smaletz, Maria D P E Diz, Claudio C do Carmo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancerAndrew M Scott, Greg Wiseman, Sydney Welt, et al.
Nature Medicine|May 27, 2025
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialEdmond M Kwan, Sarah W S Ng, Sofie H Tolmeijer, et al.
Nature Communications|November 24, 2019
Deletion of intestinal Hdac3 remodels the lipidome of enterocytes and protects mice from diet-induced obesityMercedes Dávalos-Salas, Magdalene K Montgomery, Camilla M Reehorst, et al.
Theranostics|October 14, 2020
First clinical study of a pegylated diabody <sup>124</sup>I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancersAndrew M Scott, Timothy Akhurst, Fook-Thean Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal CancerMarika Ciprotti, Niall C Tebbutt, Fook-Thean Lee, et al.
Nature Medicine|March 13, 2018
Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signalingPernilla Roswall, Matteo Bocci, Michael Bartoschek, et al.
Pageof 36

Showing results (321-330 of 360) with videos related to

Sort By:
Pageof 36
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinomaGeoffrey Chong, Fook Thean Lee, Wendie Hopkins, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 9, 2013
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemiaDavid S Ritchie, Paul J Neeson, Amit Khot, et al.
The Lancet. Oncology|September 13, 2024
[<sup>89</sup>Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trialBrian Shuch, Allan J Pantuck, Jean-Christophe Bernhard, et al.
Gynecologic Oncology|June 1, 2015
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinomaOren Smaletz, Maria D P E Diz, Claudio C do Carmo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancerAndrew M Scott, Greg Wiseman, Sydney Welt, et al.
Nature Medicine|May 27, 2025
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialEdmond M Kwan, Sarah W S Ng, Sofie H Tolmeijer, et al.
Nature Communications|November 24, 2019
Deletion of intestinal Hdac3 remodels the lipidome of enterocytes and protects mice from diet-induced obesityMercedes Dávalos-Salas, Magdalene K Montgomery, Camilla M Reehorst, et al.
Theranostics|October 14, 2020
First clinical study of a pegylated diabody <sup>124</sup>I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancersAndrew M Scott, Timothy Akhurst, Fook-Thean Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal CancerMarika Ciprotti, Niall C Tebbutt, Fook-Thean Lee, et al.
Nature Medicine|March 13, 2018
Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signalingPernilla Roswall, Matteo Bocci, Michael Bartoschek, et al.
Pageof 36